The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids

This study has been completed.
Sponsor:
Information provided by:
Gateway Health Alliance
ClinicalTrials.gov Identifier:
NCT00526682
First received: September 6, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.


Condition Intervention
Obesity
Overweight
Dyslipidemia
Dietary Supplement: Irvingia/cissus combo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases

Resource links provided by NLM:


Further study details as provided by Gateway Health Alliance:

Primary Outcome Measures:
  • Weight change [ Time Frame: 10 weeks ]

Secondary Outcome Measures:
  • Blood lipids Body fat Fasting blood glucose [ Time Frame: 10 weeks ]

Enrollment: 72
Study Start Date: January 2007
Study Completion Date: April 2007
Arms Assigned Interventions
Active Comparator: 1
Comparison of actives for synergy
Dietary Supplement: Irvingia/cissus combo
Other Name: Irvingia cissus combo

Detailed Description:

To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects.

The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group):

Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG).

The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks.

No major dietary changes or exercises were suggested during the study.

  Eligibility

Ages Eligible for Study:   19 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI>26kg/m2

Exclusion Criteria:

  • Diabetics
  • Pregnant and lactating
  • Subjects on any other weight loss program
  • Following any specific low calorie diet
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00526682

Sponsors and Collaborators
Gateway Health Alliance
Investigators
Principal Investigator: Julius E OBEN, PhD University of Yaounde 1
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00526682     History of Changes
Other Study ID Numbers: GHACT010
Study First Received: September 6, 2007
Last Updated: September 6, 2007
Health Authority: Cameroon: Ministry of Public Health

Keywords provided by Gateway Health Alliance:
Antiobesity
Weight loss

Additional relevant MeSH terms:
Obesity
Overweight
Dyslipidemias
Overnutrition
Nutrition Disorders
Body Weight
Signs and Symptoms
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on October 02, 2014